Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6888155 | 0.98 | ALDH1A1 (0.49) | HSD17B10HTR3EHTR3BCYP1A2HTR1A | |
| SCHEMBL28802737 | 0.90 | TDP1 (0.49) | HSD17B10HTR3EHTR3BCYP1A2HTR1A | |
| SCHEMBL9030269 | 0.89 | HSD17B10 (0.45) | HSD17B10HTR3EHTR3BCYP1A2HTR1A | |
| Nitric Acid SCHEMBL8769140 | 0.88 | ALDH1A1 (0.39) | HSD17B10HTR3EHTR3BCYP1A2HTR1A | |
| SCHEMBL4216264 | 0.76 | HSD17B10 (0.48) | HSD17B10HTR3EHTR3BCYP1A2HTR1A | |
| SCHEMBL10818264 | 0.75 | MEN1 (0.44) | HSD17B10CYP1A2TSHRNFKB1ALDH1A1 | |
| SCHEMBL296285 | 0.73 | ADRB1 (0.44) | TSHRHTR7ALDH1A1HPGDLMNA | |
| SCHEMBL3319952 | 0.73 | HSD17B10 (0.42) | HSD17B10HTR3EHTR3BCYP1A2HTR1A | |
| Bromide SCHEMBL9444674 | 0.73 | HTR1A (0.54) | HSD17B10HTR3EHTR3BCYP1A2HTR1A | |
| SCHEMBL16395801 | 0.73 | HSD17B10 (0.42) | HSD17B10HTR3EHTR3BCYP1A2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730691-B1 | OPHTHALMIC SOLUTION FOR INHIBITING VISUAL ANOMALIES EXPERIENCED BY AN INDIVIDUAL WHO UNDERGONE REFRACTIVE EYE SURGERY COMPRISING ALPHA ADRENERGIC BLOCKING AGENTS, ONE OR MORE ANTI-IRRITANT AGENTS, AND ONE OR MORE ANTI-INFLAMMATORY | GALIN MILES A (US) | 2004-05-04 | — | — | US | claimed |
| JP-2003535817-A | — | — | 2003-12-02 | — | — | JP | claimed |
| EP-1047406-B1 | AUTOCLAVABLE PHARMACEUTICAL COMPOSITIONS CONTAINING A CHELATING AGENT | NOVARTIS AG (CH) | 2003-04-23 | — | — | EP | claimed |
| EP-1255540-A1 | OPHTHALMIC USE OF ALPHA ADRENERGIC BLOCKING AGENTS | Galin, Miles A. (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001058438-A1 | OPHTHALMIC USE OF ALPHA ADRENERGIC BLOCKING AGENTS | GALIN MILES A (US) | 2001-08-16 | — | — | WO | claimed |
| JP-4234316-A | — | — | None | — | — | JP | disclosed |
| EP-4721725-A2 | TREATMENT OF PRESBYOPIA AND MYDRIASIS WITH PHENTOLAMINE | Opus Genetics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12576066-B2 | Methods and compositions for treatment of mydriasis | OPUS GENETICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12576067-B2 | Methods and compositions for treatment of mydriasis | OPUS GENETICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3870170-B1 | TREATMENT OF PRESBYOPIA AND MYDRIASIS WITH PHENTOLAMINE | OPUS GENETICS INC (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4578441-A1 | TREATMENT OF LOCALIZED PAIN | PlantTec Medical GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| US-20250161275-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS | OPUS GENETICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-1255540-A1 | OPHTHALMIC USE OF ALPHA ADRENERGIC BLOCKING AGENTS | Galin, Miles A. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001058438-A1 | OPHTHALMIC USE OF ALPHA ADRENERGIC BLOCKING AGENTS | GALIN MILES A (US) | 2001-08-16 | — | — | WO | disclosed |
| US-6203813-B1 | OPIATE ANTAGONIST, STEROIDAL ANTIINFLAMMATORY AGENT AND CARRIER; SUSTAINED RELEASE; DRUG ABUSE TREATMENT | GOOBERMAN, LANCE L. | 2001-03-20 | — | — | US | disclosed |
| US-5611796-A | Handpiece for a device for performing laser surgery of the nose | KAMAMI YVES-VICTOR (FR) | 1997-03-18 | — | — | US | disclosed |
| JP-H04234316-A | PREPARATION OF PHARMACEUTICAL COMPOSITION HAVING INCREASED RATE OF DISSOLUTION OF ACTIVE SUBSTANCES AND THUS PREPARED COMPOSITIONS | FARMA RESA SRL | 1992-08-24 | — | — | JP | disclosed |
| US-4223087-A | TREATING SURFACE WITH SOLUTION OF A FERRICYANIDE ANION AND A COMPLEXING AGENT; OXIDATION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1980-09-16 | — | — | US | disclosed |
| US-4204868-A | PHOTOLITHOGRAPHY OLEOPHILIC SILVER | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1980-05-27 | — | — | US | disclosed |
| US-4065575-A | VASODILATORS | JOULLIE INTERNATIONAL (FR) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576066-B2 | Methods and compositions for treatment of mydriasis | ADRA1D, ADRB2, ADRA2B | HSD17B10 2620/4885HTR3E 67/4885HTR3B 68/4885 |
| US-20250161275-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS | ADRB2, ADRB3, ADRB1 | HSD17B10 2277/4885HTR3E 965/4885HTR3B 387/4885 |
| US-12576067-B2 | Methods and compositions for treatment of mydriasis | ADRA1D, ADRB2, ADRA2B | HSD17B10 2696/4885HTR3E 64/4885HTR3B 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.